Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome

Trial Profile

A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARO-APOC3 (Primary)
  • Indications Hyperlipoproteinaemia type I; Hypertriglyceridaemia
  • Focus Adverse reactions; First in man
  • Sponsors Arrowhead Pharmaceuticals
  • Most Recent Events

    • 18 Nov 2019 Results (n=40), assessing RNA Interference in targeting Apolipoprotein C-III, presented at the American Heart Association Scientific Sessions 2019.
    • 18 Nov 2019 Results published in the Arrowhead Pharmaceuticals Media Release.
    • 18 Nov 2019 According to an Arrowhead Pharmaceuticals Media Release, data from this study were presented at the American Heart Association (AHA) Scientific Sessions 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top